John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

Z. L. E. van Kempen; C. E. Leurs; A. de Vries; A. Vennegoor; T. Rispens; M. P. Wattjes; J. Killestein

doi:https://doi.org/10.1111/ene.13355

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

Z. L. E. van Kempen, C. E. Leurs, A. de Vries, A. Vennegoor, T. Rispens, M. P. Wattjes, J. Killestein

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. MethodsNatalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. ResultsOne hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. ConclusionsHigher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients

Original language	English
Pages (from-to)	1196-1199
Number of pages	4
Journal	European journal of neurology
Volume	24
Issue number	9
DOIs	https://doi.org/10.1111/ene.13355
Publication status	Published - 1 Sept 2017

Keywords

JC virus
multiple sclerosis
natalizumab

Access to Document

https://doi.org/10.1111/ene.13355

Cite this

@article{0ab6890c53e5453dbb150148ef0e7389,

title = "John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients",

abstract = "Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. MethodsNatalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. ResultsOne hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. ConclusionsHigher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients",

keywords = "JC virus, multiple sclerosis, natalizumab",

author = "{van Kempen}, {Z. L. E.} and Leurs, {C. E.} and {de Vries}, A. and A. Vennegoor and T. Rispens and Wattjes, {M. P.} and J. Killestein",

year = "2017",

month = sep,

day = "1",

doi = "https://doi.org/10.1111/ene.13355",

language = "English",

volume = "24",

pages = "1196--1199",

journal = "European journal of neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

AU - van Kempen, Z. L. E.

AU - Leurs, C. E.

AU - de Vries, A.

AU - Vennegoor, A.

AU - Rispens, T.

AU - Wattjes, M. P.

AU - Killestein, J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. MethodsNatalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. ResultsOne hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. ConclusionsHigher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients

AB - Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. MethodsNatalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. ResultsOne hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. ConclusionsHigher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients

KW - JC virus

KW - multiple sclerosis

KW - natalizumab

UR - http://www.scopus.com/inward/record.url?scp=85023646437&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/ene.13355

DO - https://doi.org/10.1111/ene.13355

M3 - Article

C2 - 28707781

SN - 1351-5101

VL - 24

SP - 1196

EP - 1199

JO - European journal of neurology

JF - European journal of neurology

IS - 9

ER -

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

Abstract

Keywords

Access to Document

Other files and links

Cite this